•   
  •   

Entertainment Biontech share: How the company could revolutionize cancer medicine!

12:15  31 october  2020
12:15  31 october  2020 Source:   fool.de

Linda Nolan lies in bed and thinks about the future amid cancer battle

  Linda Nolan lies in bed and thinks about the future amid cancer battle Linda Nolan has admitted she is worried this Christmas could be her last due to her liver cancer battle. The singer, 61, spoke to Bella Magazine about her illness and how she tries to cope, admitting: 'I lie in bed and I wonder how long I'll be here, if I'll see my great-nieces and nephews grow into adults, or if this Christmas is going to be my last.' Linda went on to add that she regrets not having children. She said: 'It's nobody's fault I just left it too late. I put my career in the way. It's my biggest regret in life but I don't dwell on it.

At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies "We founded BioNTech to advance and develop key technologies and bring together the right people to realize our vision for the future of cancer medicine ".

Follow us on our mission to revolutionize cancer immunotherapy and stay up to date on our latest news and events. Press Releases. Follow us on our mission to revolutionize medicine . BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Ind…

Biontech (NASDAQ: Biontech

) is currently in the limelight primarily due to its novel mRNA Covid-19 vaccine , which has apparently gone through all development phases without any problems. Should positive results from the clinical phase III study be announced in a few days, a new era could begin for medicine, because there is still no mRNA-based vaccine worldwide. Corona-Aktien gegen COVID-19 lockdown © Provided by The Motley Fool Corona stocks against COVID-19 lockdown

Biontech is primarily researching cancer therapies

It could be the start of a whole range of new drugs. Biontech works mainly on individualized cancer therapies. They are designed to help the human immune system recognize the cancer in the body and then attack it. Compared to today's methods, these therapies would represent a major step forward.

Covid-19: Vaccine will begin to be made in Melbourne next week

  Covid-19: Vaccine will begin to be made in Melbourne next week Scott Morrison has announced that manufacturing of the AstraZeneca coronavirus vaccine will begin in Melbourne next week and will be rolled out once approved.The government has signed a deal with biotech company CSL to make 30million doses of AstraZeneca's vaccine at its factory in Melbourne.

BioNTech also stands to receive future milestone payments of up to 3 million for a potential total consideration Arcturus Therapeutics Ltd (NASDAQ: ARCT), an mRNA medicines company , said The company said under the guidance of the Health Sciences Authority of Singapore, it plans to start

Cancer -Vaccine Maker BioNTech Considering an IPO in U.S. BioNTech AG, a European biotechnology company that has drug-development partnerships with Pfizer Inc No final decisions have been made and BioNTech could remain private for longer or choose to raise financing privately

A success in the development of a Covid-19 vaccine would give Biontech financially stronger and thus probably the breakthrough in the development of many other vaccines that are currently still in clinical trials. The Biontech- share could do justice to its already anticipated status of a billion euro corporation relatively quickly.

These are Biontech's hopes.

The company has already started clinical studies with several candidates. Including BNT111, a cancer vaccine based on the mRNA. It is being developed for the later treatment of advanced melanoma in patients with metastatic tumors and for support after tumor resection. It is designed to trigger an immune response to four melanoma-associated antigens. The vaccine has already shown positive results in a phase I study.

Olivia Newton-John opens up about her battle with cancer

  Olivia Newton-John opens up about her battle with cancer Olivia Newton-John has opened up about 'living with cancer' and losing friends to the disease in a new interview with the Mirror. The 73-year-old, who has been diagnosed with cancer three times since 1992, recently lost close friend Kelly Preston to breast cancer.Olivia famously starred alongside Kelly's husband John Travolta in Grease and has been friends with the couple for decades.

The U.S. company and its German rival BioNTech plan to use RNA as a messenger inside cells to produce an immune reaction. Moderna Wants to Transform the Body Into a Vaccine-Making Machine. The U.S. company and its German rival BioNTech shares have more than doubled.

Share to Linkedin. According to the American Cancer Society, the estimated number of new cases of Because it was discovered that a person’s unique immune system can impact these cells, two formerly disparate medical fields — cancer research and immunotherapy — have become interrelated.

BNT112, also an mRNA cancer vaccine, is currently being investigated in a first clinical phase 1/2 study in patients with metastatic, castration-resistant prostate cancer and localized prostate cancer.

BNT113 is in an initial clinical investigation conducted by the University of Southampton and will later be used in the treatment of head and neck cancer.

Video: Corona, flu or cold? These are the differences (glomex)

The mRNA cancer vaccine BNT122 is already in the second clinical development phase and, if successful, should be used in combination with pembrolizumab for the treatment of metastatic melanoma and other solid tumors. Biontech is developing the candidate in collaboration with Genentech.

BNT114 is another mRNA-based cancer vaccine that is in clinical development phase one and could be used to treat breast cancer. It is being tested both as a monotherapy and in combination with the immunotherapy BNT122.

Added to this is BNT115, which is currently being investigated in a phase I study for the treatment of ovarian cancer. It is also based on mRNA technology.

Coronavirus vaccine production begins in Australia before Oxford-AstraZeneca's products last stage of approval

  Coronavirus vaccine production begins in Australia before Oxford-AstraZeneca's products last stage of approval Coronavirus vaccines could be available by mid-next year, with an Australian company starting to make doses of one product before it has even been approved. Manufacturing of Oxford University's vaccine began in Victoria today.The company, CSL, is making about 30 million doses of the Oxford-AstraZeneca vaccine despite it still going through phase-three clinical trials.The results from these trials won't be known until the end of the year. And if they're positive, the vaccine will still need to get approval from the Therapeutic Goods Administration (TGA).

About BioNTech . Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel

“ How do we create an environment that can ensure the most important tenet in medicine : Do no harm?” Finally, the project ran into a bigger obstacle The company said that Watson for Oncology can extract and summarize substantial text from patient records, though the information must be

In collaboration with

Sanofi

(NYSE: BNT131), BNT131 is currently being developed as an intratumoral immunotherapy for the treatment of solid tumors. The vaccine uses mRNA to encode the cytokines IL-12sc, IL-15sushi, IFNα and GM-CSF. By increasing the concentration of these cytokines in the tumor's microenvironment, the immune system can more easily identify and fight cancer.

BNT131 is being investigated in a phase one clinical basket study as monotherapy in patients with advanced melanoma and in combination with an anti-PD-1 / PD-L1 checkpoint inhibitor in patients with advanced melanoma and certain solid tumors.

The candidates BNT311 and BNT312 are antibody therapies and are currently in clinical development phase one. They are being researched together with Genmab (NASDAQOTH: 565131) and, if successful, will be used against solid tumors.

Conclusion

In addition to these many candidates, there are many more in the pre-clinical investigation. In addition to a Covid-19 vaccine, Biontech could bring many other products onto the market in the future, and since they have been very unique so far, they could become a great financial success. The post Biontech share: How the company could revolutionize cancer medicine!

appeared first on

The Motley Fool Germany .

Christof Welzel has no position in any of the stocks mentioned.

The Motley Fool has no position in any of the stocks mentioned.

X1X1 Motley Fool Germany 2020 X1

Covid-19. Five questions about the vaccine promised by Pfizer and BioNTech laboratories .
© Illustration DADO RUVIC / REUTERS One dose of Pfizer vaccine. The Pfizer and BioNTech laboratories announced this Monday, November 9 that their vaccine was 90% effective against Covid-19. What does this vaccine consist of? When will it be available? Is he so sure? We take stock of the questions that arise on this subject. The announcement has raised tremendous hope.

usr: 1
This is interesting!